Dr. Siddharth Kaul, MD

Dr. Kaul practices at SSM Cancer Care South Schc - HOPD in Fenton, Missouri.

Dr. Kaul's NPI, 1245493402, was assigned on July 8, 2008. Dr. Kaul holds Oregon license MD221827.

Dr. Kaul's primary practice is SSM Cancer Care South Schc - HOPD, at 1011 Bowles Ave, Fenton, MO 63026.

Dr. Kaul's primary practice is SSM Cancer Care South Schc - HOPD in Fenton, Missouri. Dr. Kaul is also affiliated with SSM Health St. Clare Hospital - Fenton. The medical group on file is SSM Health Medical Group. Dmand AI also links Dr. Kaul to 5 more hospitals, 12 medical groups, 9 group practices and clinics and 1 skilled nursing facility, each named with a free account. Dr. Kaul's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kaul practices, 17 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Kaul's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dmand AI has Dr. Kaul's licenses on file in 5 states: Oregon, Florida, Illinois, Missouri and Texas.

CMS data shows 559 Medicare services from Dr. Kaul across 10 procedure codes in 2024, for 360 Medicare patients. Medicare paid $43,512 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 360 Medicare patients who saw Dr. Kaul in 2024. The largest group is 75 to 84, with 128 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 23% are also on Medicaid. Their average risk score is 2.02, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kaul's median patient age at 67, with 65% women.

In 2024, Dr. Kaul wrote 2,942 Medicare Part D claims for 451 patients. 87% of them were for generic drugs. CMS names the drug for 2,705 of them, across 64 drugs with 11 or more claims each, at $600,368 in total drug cost. In 2023, CMS named 2,279 claims across 55 drugs.

Dr. Kaul accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kaul as offering telehealth.

Dmand AI links Dr. Kaul to 5 clinical trials. 2 are still active or recruiting. Conditions studied include Alzheimer Disease, Tauopathies and Plaque, Amyloid. Eli Lilly and Company sponsors the most, 5. Open Payments lists research payments to Dr. Kaul that name 5 trials.

CMS Open Payments shows 1,077 general payments to Dr. Kaul from 31 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 82% of the total. Abbvie Inc. paid the most, $200,173. It also lists 21 research payments totaling $198,491 from 2016 to 2023, naming 5 clinical trials.